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Abstract 
Cancer cachexia has two main components: anorexia and metabolic alterations. The main 
changes associated with the development of this multi-organic syndrome are glucose intolerance, 
fat depletion and muscle protein hypercatabolism. The aim of this paper is to review the more 
recent therapeutic approaches designed to counteract the wasting suffered by the cancer patient 
with cachexia. Among the most promising approaches we can include the use of ghrelin agonists, 
beta-blockers, beta-adrenergic agonists, androgen receptor agonists and anti-myostatin peptides. 
The multi-targeted approach seems essential in these treatments, which should include the 
combination of both nutritional support, drugs and a suitable program of physical exercise, in 
order to ameliorate both anorexia and the metabolic changes associated with cachexia. In 
addition, another very important and crucial aspect to be taken into consideration in the design 
of clinical trials for the treatment of cancer cachexia is to staging cancer patients in relation with 
the degree of cachexia, in order to start as early as possible this triple approach in the course of 
the disease, even before the weight loss can be detected. 
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 Cachexia, according to an international consensus,1 ‘‘is 
a complex metabolic syndrome associated with 
underlying illness and characterized by loss of muscle 
with or without loss of fat mass. Anorexia, inflammation, 
insulin resistance and increased muscle protein 
breakdown are frequently associated with cachexia. 
Cachexia is distinct from starvation, age-related loss of 
muscle mass, primary depression, malabsorption and 
hyperthyroidism and is associated with increased 
morbidity”.1 Although anorexia represents a very 
important event in the development of cachexia, it has 
been proven that total parenteral nutrition does not stop 
the loss of body weight. Therefore, it seems quite evident 
that metabolic alterations present in the patient (increased 
energy inefficiency, insulin resistance and abnormal 
carbohydrate metabolism, adipose tissue dissolution and 
hypertriglyceridemia, and muscle wasting) have a key 
role in the development of cachexia.2 Moreover, some of 
the alterations are also a result of the chemotherapeutic 
treatment.3,4 Bearing this in mind, the development of 
different therapeutic approaches has focused, either on 
increasing food intake or on reversing catabolism and 
increasing the anabolic drive of the cancer patient.  
Drugs modulating cytokine action 
TNF- (Tumor necrosis factor alpha), IL-1 (interleukin 
1), IL-6 (interleukin 6) and interferon-gamma (IFN-) are 
the main cytokines implicated in cachexia. Interestingly, 
these cytokines share the same metabolic effects and their 
activities are closely interrelated. In many studies, they 
exhibit synergic effects when administered together. 
Therefore, therapeutic strategies have been based on 
either blocking their synthesis or their action. Weight loss 
in patients with oesophageal tumors is related to the 
levels of the cytokines.5 In fact, cytokines are able to act 
on multiple target sites such as bone marrow, myocytes, 
hepatocytes, adipocytes, endothelial cells and neurons, 
where they generate a complex cascade of responses 
leading to the wasting associated with cachexia. Using 
anti-TNF strategies such as etanercept (fusion protein 
directed against p75 TNF- receptor) has led to a poor 
clinical outcome in cancer patients.  However, a clinical 
pilot study with several advanced malignancies involving 
patients treated with etanercept combined with an 
antitumor agent (docetaxel),6 showed less fatigue and 
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Another phase II trial with infliximab - an anti-TNF- 
monoclonal antibody - was unsuccessful in improving 
symptoms of cachexia (lean body mass) in pancreatic 
cancer patients.8 Survival in cancer patients is inversely 
correlated with circulating IL-6 levels.9  In a mouse 
model of cancer cachexia, tocilizumab, an IL-6 
monoclonal antibody, improved cachexia.10 A 
humanized monoclonal anti-IL-6 antibody increased 
hemoglobin levels and prevented muscle wasting in 
cancer patients.11 In preclinical and in a Phase II trial, 
ALD518 targeting IL-6 appears well tolerated and 
ameliorates NSCLC-related anemia and cachexia.12 On 
the same lines, a phase II clinical trial with Ruxolitinib - 
an inhibitor of Janus kinases (JAKs) activators of the 
STAT transcription factor - in patients with tumor-
associated chronic wasting diseases is now on-going.13 
IL-6 intracellular signaling pathway takes place via 
activation of the Janus kinases. Targeting both TNF- 
and IL-6 by means of a broad-spectrum peptide nucleic 
acid (OHR118, OHR Pharma), resulted in an increase in 
both body weight and physical performance in patients 
with advanced cancer in a phase II trial.14,15 In a pre-
clinical mouse model of pancreatic cancer cachexia, 
Greco et al. have described that blockade of TGF-, 
lessens cachexia, reducing mortality and metabolic 
alterations.16 In fact, according to Waning, TGF-β 
mediates muscle weakness associated with bone 
metastases in mice.17 Indeed, during tumor-induced bone 
destruction, TGF-β upregulates Nox4 - an NADPH 
oxidase - resulting in alterations in skeletal muscle 
proteins (oxidation). Among these proteins, the 
ryanodine receptor/calcium (Ca2+) release channel 
(RyR1) is oxidized. The altered RyR1 channels leak 
Ca2+, resulting in lower intracellular signaling required 
for adequate muscle contraction.17 The production of the 
cytokines mentioned above, known as catabolic pro-
inflammatory cytokines, is not the only factor involved 
in the metabolic changes associated with cancer 
cachexia. Indeed, the so-called anti-inflammatory 
cytokines, such as IL-4, -10 -12 and -15, are also 
involved. Indeed, IL-15 has been reported to be an 
anabolic factor for skeletal muscle.18,19 IL-15 decreases 
protein degradation and DNA fragmentation while 
increases UCP3 (uncoupling protein-3) expression in 
skeletal muscle.18 The action of the cytokine is directly 
upon skeletal muscle.20 Pre-clinical studies indicate that 
IL-15 leads to an improvement of muscle mass and 
performance in tumor-bearing animals.19 Martinez-
Hernandez et al. have demonstrated a relevant 
association between serum IL-15 and changes in weight 
and muscle mass in cancer patients, suggesting a possible 
role of the cytokine as a body composition marker in 
weight-losing cancer patients.21 
Drugs modulating appetite 
In humans, megestrol acetate  - a synthetic, orally active 
derivative of the naturally occurring hormone 
progesterone - improves appetite, caloric intake and 
nutritional status.22 The mechanism that mediates the 
weight gain is mostly unknown, although it has been 
proposed that it may be partially mediated by 
neuropeptide Y (NPY), a potent central appetite 
stimulant. Interestingly, in experimental animals, 
megestrol acetate increases not only food intake but also 
lean mass and physical performance.23 Nanocrystal 
suspensions of megestrol acetate are easy to use and 
represent an improvement in bioavailability.24 Megestrol 
acetate is the standard drug in cancer cachexia treatment 
in many countries over the world.25 The orexigenic 
mediator ghrelin, a novel endogenous ligand for the 
growth hormone secretagogue receptor, and secreted by 
the stomach and pancreas, has been reported as having a 
pivotal role in increasing appetite and, therefore, food 
intake. Besides, this peptide has important metabolic 
effects and regulates energy metabolism through growth 
hormone-dependent and -independent mechanisms.26 
Thus, administration of ghrelin constitutes a new 
therapeutic strategy for the treatment of cancer 
cachexia.27  Pre-clinical studies have shown that ghrelin 
administration to cachectic tumor-bearing animals results 
in an improvement in both appetite and body weight, 
together with an improvement in lean body mass.28 In 
addition, ghrelin administration to rats prevents cisplatin-
induced mechanical hyperalgesia – increased pain 
sensitivity – and cachexia.29 In fact, cisplatin-induced 
anorexia is mediated through reduced hypothalamic 
ghrelin secretion. In addition, ghrelin seems to attenuate 
gastrointestinal epithelial damage induced by 
doxorubicin.30 These results support ghrelin as a 
protective factor against the toxic effects of 
chemotherapeutic agents. Several clinical trials with 
ghrelin or ghrelin mimetics have been performed or are 
currently ongoing. A couple of phase II randomized, 
placebo-controlled, double-blind studies using an oral 
ghrelin mimetic, anamorelin (Helsinn Therapeutics), a 
ghrelin receptor agonist that can be administered orally, 
have led to positive results in non-small cell lung cancer 
(NSCLC) patients showing an improvement in lean body 
mass, total body mass and hand grip strength.31 However, 
two double-blinded phase II trials (ROMANA 1 & 2) in 
incurable stage II/IV NSCLC patients, showed that 
anamorelin (100 mg/day for 12 weeks) increased body 
weight, improved FAACT anorexia/cachexia scores,31,32 
but failed to improve handgrip strength.33 In a post hoc 
analysis of the two phase II studies, Temel et al. 
concluded that anamorelin increased both lean and fat 
mass as well as decreased muscle fatigue.33 Interestingly, 
Takayama et al. reported, in a phase-II randomized trial 
where NSCLC patients were daily given 100 mg of 
anamorelin, an increase in lean body mass, appetite, 
quality of life and performance status following 
anamorelin administration.34  In addition, significant 
elevations in both IGF-1 and IGFBP-3 plasma 
concentrations were observed, suggesting an 
improvement in protein synthesis. Another appetite 
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macimorelin -, an oral peptidomimetic growth hormone 
secretagogue (Aeterna Zentaris), now in phase II, and the 
endpoints of the trial being changes in body weight, IGF-
1 levels and quality of life.35 Finally, Asubio 
Pharmaceuticals is involved in a phase-II clinical trial 
with synthetic human ghrelin (SUN11031) in COPD 
patients.36 
Drugs acting on other metabolic targets 
Pre-clinical studies using formoterol - a 2-adrenergic 
agonist with low cardiac toxicity - have shown that the 
drug can reverse muscle wasting associated with cancer. 
37,38. Essentially, formoterol treatment increases the rate 
of protein synthesis while inhibiting the rate of muscle 
proteolysis. Interestingly, this 2-agonist is also able to 
diminish the increased rate of muscle apoptosis present 
in tumor-bearing animals, together with facilitating 
muscle regeneration by stimulating satellite cells.38,39 A 
combination treatment of formoterol and soluble 
myostatin receptor ActRIIB has been able to completely 
reserve muscle wasting in tumor-bearing rats,40 the 
results emphasizing the importance of combining drugs 
in the treatment of cancer cachexia. A phase-IIa study 
investigating the effects of a combination of formoterol 
and megestrol acetate (APD209) in 13 cachectic cancer 
patients has been undertaken by Acacia Pharma.41  Six of 
the seven patients that completed the treatment period 
showed improved muscle size and strength, and three 
patients had improved levels of daily physical activity.41 
Erythropoietin (EPO) administration to cancer patients -
- with subnormal or even normal hemoglobin levels -- 
results in clinical benefit. Interestingly, Kanzaki et al. 
have shown that EPO --in a pre-clinical cancer cachexia 
model-- decreases the production of the pro-cachectic 
cytokine IL-6.42 This may be linked with the attenuation 
of cachectic manifestations. EPO treatment also 
improves metabolic and exercise capacity via an 
increased erythrocyte count.42 In a pre-clinical mouse 
model of cancer cachexia, the combination of EPO 
administration and aerobic exercise has led to a 
significant decrease of muscle wasting.43 Patients with 
cancer cachexia have major abnormalities in heart mass 
and function, the so-called cardiac cachexia. In fact, 
cardiac arrest is the main cause of death - at autopsy - 
associated with cancer. From this point of view, several 
drugs have been used to counteract cardiac cachexia 
associated with cancer. Inhibitors of the angiotensin-
converting enzyme (ACE) have been tested in preclinical 
models with success in increasing both muscle and fat 
mass.44,45 Some evidence also exists concerning the 
potential of ACE inhibitors to ameliorate cancer cachexia 
in NSCLC patients.46 Angiotensin receptor blockers can 
also be used in the treatment of cachexia.  Thus, one of 
this compounds, Telmisartan, can be used as an add-on 
therapy with 5-fluorouracil,47 or cisplatin,48 or other 
traditional chemotherapeutic agents. Telmisartan inhibits 
TNF--induced IL-6 expression at the transcriptional 
level through the activation of PPAR-γ.49 NF-κB 
signaling plays an important role during skeletal muscle 
atrophy and fat lipolysis. On these lines, pyrrolidine 
dithiocarbamate (PDTC, an inhibitor of the transcription 
factor) is able to attenuate attenuated cancer cachexia 
symptom in C26 tumor-bearing mice models in vivo 
without influencing tumor volume interfering with 
muscle atrophy and fat lipolysis.50 Beta-blockers can 
reduce body energy expenditure and improve the 
efficiency of substrate utilization. Some of them do 
combine many different pharmacological effects. 
Espindolol (MT-102, PsiOxus Therapeutics) is a non-
specific β1/β2 adrenergic receptor antagonist that exhibits 
effects through β and central 5-HT1α receptors to 
demonstrate pro-anabolic, anti-catabolic, and appetite-
stimulating actions.51 The ACT-ONE trial showed that 
espindolol 10 mg twice daily was able to revert weight 
loss, improve fat-free mass, and maintain fat mass and 
improve handgrip strength in cachectic patients with non-
small cell lung cancer or colorectal cancer.52 VT-122 
combines a non-selective beta-blocker, propranolol - 
used in controlling high blood pressure - and etodolac, a 
COX-2 inhibitor. Data from a phase II clinical study 
clearly show an improvement in lean body mass in non-
small cell lung cancer patients.53 Even though derivatives 
of gonadal steroids have important side effects, such as 
masculinization, fluid retention and hepatic toxicity, 
treatment with these drugs facilitates nitrogen protein 
accumulation, therefore counteracting the progressive 
nitrogen loss associated with muscle wasting. In fact, 
non-steroidal selective androgen receptor modulators 
(SARMs) hold promise as a new class of function 
promoting anabolic therapies for several clinical 
conditions that manifest muscle wasting. In a phase IIb, 
double-blind, placebo-controlled study, involving non-
small-cell lung cancer (NSCLC), colorectal cancer, non-
Hodgkin’s lymphoma, chronic lymphocytic leukemia, or 
breast cancer patients, Enobosarm treatment led to 
significant improvements in lean body mass, physical 
function, and quality of life54. These positive results have 
led to the design of phase III trials. On these lines, 
Crawford et al. reported a study design and rationale for 
the phase III clinical development program of 
Enobosarm, for the prevention and treatment of muscle 
wasting in oncology patients (POWER Trials).55  To 
assess enobosarm’s effect on both prevention and 
treatment of muscle wasting, in each pivotal POWER 
trial, subjects will receive placebo or Enobosarm 3 mg 
orally once daily for 147 days. Physical function will be 
assessed as stair climb power, and lean body mass 
assessed by dual-energy X-ray absorptiometry (DXA), 
these being the co-primary efficacy endpoints in both 
trials assessed at day 84.55 Preliminary data report an 
increase in lean body mass and improvement in SCP 
(POWER1).  POWER2 also shows an increase in lean 
body mass, while no clinical improvement in the stair 
climb power test and handgrip strength is seen.56  
Myostatin, a TGF- super-family member, is a negative 
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myostatin inhibitors induce muscle hypertrophy specially 
through effects on myofibrillar protein synthesis rather 
than through an stimulation of satellite cell 
proliferation.57,58 Bearing this in mind, anti-myostatin 
strategies have been used in clinical trials involving 
cachectic patients. From this point of view, a phase II 
study in sarcopenic patients has been undertaken using 
AMG745, a peptibody against myostatin.59 Similarly, 
Acceleron Pharma has performed a phase I study with 
ACE031, a soluble Activin receptor type IIB.60  
Bimagrumab or BYM338, an activin II receptor 
antibody, has also been studied in relation with cachexia 
in patients with inclusion myositis.61 BYM338 is able to 
bind ActRIIB 200-times better than ActRIIA, promoting 
skeletal muscle hypertrophy when administered in vivo. 
When administered in association with glucocorticoids, 
BYM338 was able to prevent skeletal muscle mass loss 
and preserved muscle function, facilitating the recovery 
from muscle atrophy.62 A humanized monoclonal 
antibody LY2495655 has been used in sarcopenic 
patients in a phase II trial, involving subjects who 
recently reported falls and low muscle strength and 
power.63 Patients receiving the antibody showed an 
increase in lean mass and a significant improvement of 
muscle power expressed as improved stair-climbing 
time, fast gait speed, and chair rise with arms. A phase II 
study is now being held in pancreatic cancer patients 
although no results are yet available.64 Increased 
proteolysis in skeletal muscle during cachexia involves 
activation of the ubiquitin/proteasome system in muscle.2 
Taking this into consideration, inhibitors of this 
proteolytic system such as peptide aldehyde, lactacystin 
and -lactone – which effectively can block up to 90% of 
the degradation of normal proteins and short-lived 
proteins in the cells - could be potential drugs for the 
treatment of muscle wasting.65 However, the toxicity of 
such compounds is fairly high, since they are not specific 
inhibitors of the proteolytic system in muscle tissue. 
Bearing this in mind, a drug that could specifically block 
myofibrillar protein degradation is still waiting to be 
found. Inhibitors of the proteasome have been used as 
anti-cancer drugs - since the proteasome has a main role 
in cell division - in multiple myeloma patients.  The use 
of these drugs has led to contradictory results in the 
treatment of muscle wasting in pre-clinical models. Thus, 
bortezomib did not show any significant effects in the 
treatment of cancer cachexia in rats bearing the cachectic 
Yoshida hepatoma AH-130 ascites tumor model.66 
Conversely, carfilzomib inhibits skeletal muscle 
proteolysis and apoptosis reducing cachexia in a pre-
clinical mouse model.67 A phase Ib investigation showed 
promising results with the MEK inhibitor binimetinib in 
patients with advanced or metastatic biliary tract 
cancer.68 Cancer cachexia and type II diabetes share 
common metabolic characteristics, including weight loss, 
insulin resistance and increased hepatic gluconeogenesis.  
From this point of view, recent interest has developed 
around anti-diabetic drugs - such as metformin - for the 
treatment of muscle wasting in cancer.  An interesting 
study reveals that metformin improves protein 
metabolism in skeletal muscle in tumor-bearing rats.69  
A very innovative and revolutionary strategy to fight 
muscle wasting in cancer is the use of stem cells with the 
aim of replacing degenerated muscle tissue.70 While adult 
stem cells are tissue-specific and have limited capacity to 
be expanded, ex vivo pluripotent stem cells can 
differentiate into any cell type while possessing 
unlimited in vitro self-renewal. Scott et al. described a 
methodology for large-scale isolation of satellite cells 
from skeletal muscle70, which could then be applied as a 
therapeutic strategy to stimulate muscle regeneration.71 
Another interesting approach that has led to promising 
results in pre-clinical models of cancer cachexia is the use 
of statins such as simvastatin. Indeed, in a study 
involving the cachectic Yoshida AH-130 ascites 
hepatoma has shown that simvastatin attenuated body 
weight loss and preserved muscle mass.72 
The use of nutrition 
Nutrition is an essential element in cancer care, and 
patients report a high interest and need; however, a recent 
study has shown that many patients do not have access to 
high-quality nutrition therapy either during or after 
cancer treatment.73 While some studies demonstrate a 
beneficial effect for nutritional advice,74,75 other studies 
shown - a two-year randomized controlled trial - that 
early dietary counseling was efficient in increasing intake 
but had no beneficial effect on mortality or secondary 
outcomes.76 While standard nutrition supplements have 
not led to positive results in cancer cachexia, the use of 
nutrients in combination with nutraceuticals - the so-
called specialized nutrition - has given more positive 
results. Omega3-polyunsaturated fatty acids (PUFA), 
present in large amounts in fish oil, have been proposed 
as very active in reducing either tumor growth or muscle 
wasting. An improvement in the lean body mass and 
improved quality of life was observed in a randomized 
doubled blind trial using a protein and energy dense 
omega3-fatty acid-enriched oral supplement,77 provided 
that its consumption was equal or superior to 2.2 g 
eicosapentaenoic acid (EPA)/day. However, data arising 
from a large, multicentre, double-blind placebo-
controlled trial indicate that EPA administration alone is 
not successful in the treatment of weight losing patients 
with advanced gastrointestinal or lung cancer.78 
Moreover, a meta-analysis based on five trials concluded 
that there were insufficient data to establish whether oral 
EPA was better than placebo.79 Comparisons of EPA 
combined with a protein energy supplementation versus 
a protein energy supplementation (without EPA) in the 
presence of megestrol acetate provided no evidence that 
EPA improves symptoms associated with the cachexia 
syndrome often seen in patients with advanced cancer.80 
In spite of this, several recent trials suggest that EPA-
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A multitarget approach including physical exercise 
During the last years, it has become apparent that a 
combination of nutrition, nutraceuticals and drugs is a 
much-preferred therapeutic approach than just looking 
for a single drug "magic bullet". In fact, the treatment of 
cancer cachexia has to involve, not only drugs and/or 
nutrients, but also a possibilistic program of physical 
exercise84–86. Indeed, in cancer patients - either suffering 
from cachexia or not - an exercise program can improve 
their quality of life.87,88 This is accomplished by inducing 
metabolic alterations that result in changes in body 
composition. A study has shown clear benefits - on 
cachectic cancer (head and neck) patients - of an exercise 
program (12 weeks: 2–3 sets of 8–15 repetition 
maximum of seven conventional exercises).89 Indeed, 
with an increase of 4.2% of lean body mass, enhanced 
muscle strength and quality of life were observed.89 
Similarly, in the same type of cancer patients, McNeely 
et al. demonstrated improved shoulder muscle function 
following resistance exercise training.90 Exercise 
programs have also been able to increase muscle strength 
and endurance, the six-minute walk distance, up-and-go 
time, the number of arm curls, and the number of chair 
stands, In lung cancer patients.91 A systematic review 
reports beneficial effects for breast cancer survivors.92 
Concerning the mechanisms involved in the effects of 
exercise training programs, it seems very clear that an 
anti-inflammatory status is accomplished with decreases 
in pro-inflammatory cytokines - such as TNF- - and 
increases in IL-10, a clear anti-inflammatory cytokine.87 
The decrease in inflammatory status is accompanied by a 
reduction in oxidative stress.87  Elevations in IGF-1 and 
PGC-1 alpha in skeletal muscle have also been associated 
with the beneficial effects of exercise on cancer.87 
Muscaritoli et al. have defined the so-called TARGET 
approach, which is a good way of interpreting the 
multimodal approach.93 It actually integrates active 
interventions and research programs related to the onset 
and progression of cancer cachexia. This approach 
includes Teaching (nutrition, metabolic alterations in 
cancer), Awareness (of the negative impact of cancer 
cachexia), Recognition (diagnosis and staging), Genetics 
(inherited susceptibility), Exercise (physical activity) and 
Treatment.93 The MENAC (Multimodality 
Exercise/Nutrition Anti-inflammatory treatment for 
Cachexia) trial,94 represents an excellent example of a 
multimodal approach. This on-going phase III trial is 
enrolling both lung, cholangio- and pancreatic carcinoma 
cancer patients and includes nutritional counseling, oral 
nutrition supplementation (including EPA), a physical 
exercise program and an anti-inflammatory (ibuprofen) 
treatment.95 A combined multitargeted approach in a 
randomized placebo-controlled trial, using celecoxib, L-
carnitine, curcumin and lactoferrin, was able to improve 
the nutritional and immunometabolic alterations of 
cachexia, ameliorate the patient quality of life and correct 
cancer-related anemia.96 Practical (individual reports) 
multimodal care programs for cancer cachexia have been 
recently published.97 Another critical factor that may 
positively contribute to cancer cachexia treatment is a 
proper staging of the cachectic condition in cancer 
patients.27 This would allow for adequate treatment at the 
different phases of cachexia.98 Timing is very important 
and has to be carefully considered when designing the 
therapeutic approach. Any nutritional/metabolic/ 
pharmacological support should be started early in the 
course of the disease, before severe weight loss occurs, 
and appropriate treatment should be applied at every 
phase of the cachectic syndrome. More research should 
also be devoted to finding new biomarkers for cancer 
cachexia. Indeed, many cancer patients are treated only 
when a significant amount of weight loss is detected, or 
when the patients suffer from certain limitations in their 
daily living activities. Biomarkers may serve to detect the 
changes before any clinical manifestations arise, 
facilitating treatment and, possibly, improving prognosis. 
Progress has undoubtedly been made involving 
biomarkers,99 but more research is needed in this field to 
find an easily measurable - either plasmatic or urinary - 
early and specific muscle-wasting biomarker. Another 
key aspect to consider is the design of appropriate trials. 
Indeed, on-going trials have a rather heterogeneous 
design and include an excessively wide span of different 
types of tumors with different degrees of cachexia. In 
fact, a unified approach is requested in a recent consensus 
document.100 Many of the most promising drug 
candidates are entirely new molecules and, therefore, 
particular attention has to be focused on safety issues and 
not just side effects, but also long-term treatment 
associated problems, together with the issue of 
interaction with other drugs. This last point is particularly 
relevant since, as we have mentioned, the ideal treatment 
for cancer cachexia is multimodal, involving different 
drugs and nutraceuticals. Endpoints – particularly 
primary ones - are also essential. Lean body mass or, 
even better, muscle mass, together with a measurement 
of function, such as total daily physical activity are good 
candidates. 
In conclusion, the future multimodal treatment of the 
cachectic syndrome will no doubt combine different 
approaches to efficiently counteract metabolic alterations 
while improving the energy intake of the patients. 
Defining this therapeutic multimodal combination of 
factors is an exciting project that will stimulate many 
scientific efforts. 
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inflammatory treatment for Cachexia 
NPY - neuropeptide Y 
NSCLC - non-small cell lung cancer 
PDTC - pyrrolidine dithiocarbamate 
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